Morgan Stanley Reaffirms Their Buy Rating on Gilead Sciences (GILD)
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, with a price target of $175.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Vertex Pharmaceuticals. According to TipRanks, Flynn has an average return of 9.0% and a 54.42% success rate on recommended stocks.
In addition to Morgan Stanley, Gilead Sciences also received a Buy from Bank of America Securities’s Tazeen Ahmad in a report issued today. However, on April 7, Goldman Sachs maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).
Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.93 billion and a net profit of $2.18 billion. In comparison, last year the company earned a revenue of $7.57 billion and had a net profit of $1.78 billion
Read More on GILD:
Disclaimer & DisclosureReport an Issue
- Gilead: Durable HIV Franchise and Emerging Oncology Pipeline Support Buy Rating and Upside to $162 Target
- Gilead announces investment in lenacapavir by PEPFAR, The Global Fund
- Gilead put volume heavy and directionally bearish
- Gilead price target raised to $165 from $156 at Citi
- Gilead price target raised to $175 from $171 at Morgan Stanley
